Co-Authors
This is a "connection" page, showing publications co-authored by Hadi Yassine and Gheyath Nasrallah.
Connection Strength
4.578
-
Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies. Int J Infect Dis. 2021 Jan; 102:181-187.
Score: 0.910
-
Effect of multiple freeze-thaw cycles on the detection of anti-SARS-CoV-2 IgG antibodies. J Med Microbiol. 2021 Aug; 70(8).
Score: 0.240
-
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays. Front Biosci (Landmark Ed). 2021 07 30; 26(7):198-206.
Score: 0.240
-
Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep. 2021 06 04; 11(1):11837.
Score: 0.237
-
Evaluation of Antibody Response in Symptomatic and Asymptomatic COVID-19 Patients and Diagnostic Assessment of New IgM/IgG ELISA Kits. Pathogens. 2021 Feb 03; 10(2).
Score: 0.232
-
Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals. Microorganisms. 2021 Jan 25; 9(2).
Score: 0.231
-
Demographic and Clinical Characteristics of Early Travel-Associated COVID-19 Cases. Front Public Health. 2020; 8:573925.
Score: 0.230
-
Immune Modulatory Effects of Vitamin D on Viral Infections. Nutrients. 2020 Sep 21; 12(9).
Score: 0.226
-
Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2. Viruses. 2020 05 26; 12(6).
Score: 0.221
-
Demographics and Epidemiology of Hepatitis B in the State of Qatar: A Five-Year Surveillance-Based Incidence Study. Pathogens. 2019 May 21; 8(2).
Score: 0.206
-
Hepatitis B Virus Molecular Epidemiology, Host-Virus Interaction, Coinfection, and Laboratory Diagnosis in the MENA Region: An Update. Pathogens. 2019 May 11; 8(2).
Score: 0.206
-
Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar. J Immunol Res. 2019; 2019:1386740.
Score: 0.202
-
Impaired Liver Size and Compromised Neurobehavioral Activity are Elicited by Chitosan Nanoparticles in the Zebrafish Embryo Model. Nanomaterials (Basel). 2019 Jan 19; 9(1).
Score: 0.201
-
Corrigendum: Performance evaluation of five commercial assays in assessing seroprevalence of HEV antibodies among blood donors. J Med Microbiol. 2019 01; 68(1):115.
Score: 0.199
-
Performance evaluation of five commercial assays in assessing seroprevalence of HEV antibodies among blood donors. J Med Microbiol. 2018 Sep; 67(9):1302-1309.
Score: 0.195
-
Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PLoS One. 2017; 12(12):e0189033.
Score: 0.186
-
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7).
Score: 0.061
-
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621.
Score: 0.060
-
Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above. BMC Infect Dis. 2021 Jul 05; 21(1):645.
Score: 0.060
-
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience. 2021 Jun 25; 24(6):102646.
Score: 0.059
-
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infect Dis. 2021 Aug; 8(8):ofab221.
Score: 0.059
-
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861.
Score: 0.059
-
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336.
Score: 0.059